First Product Launch...generic version of Accupan Accupan sales will quickly erode by Nefopam ....potential sales replacement of $620 million US
Multiply by 60 more new product launches and CXR will easily double its sales from its rich product pipeline
OAKVILLE, ON, Nov. 23, 2015 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today that Amdipharm Mercury Limited ("AMCo") has launched Nefopam, a generic version of Accupan. Nefopam is a non-narcotic painkiller for the treatment of persistent pain that is not being controlled by other painkillers such as paracetamol or aspirin.
"When we acquired AMCo, we identified its deep pipeline as a valuable asset to accelerate Concordia's organic growth," said Mark Thompson, Concordia's Chairman and Chief Executive Officer. "Nefopam's launch, which should be the first of approximately 60 product launches we intend to initiate over the next three years, demonstrates that potential and further diversifies our international portfolio of therapeutics."